Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting

Rhea-AI Summary

Graybug Vision, Inc. (NASDAQ: GRAY) announced the presentation of preclinical data for its drug GB-401 at the ARVO Annual Meeting in Denver from May 1-4, 2022. GB-401 is a sustained-release intravitreal implant aimed at treating primary open-angle glaucoma (POAG). The presentation will include in vitro and in vivo characterizations of GB-401, showcasing its potential benefits for POAG patients. This event will allow the company to engage with the scientific community and investors, highlighting their innovative approach to ocular disease therapies.

Positive

• Preclinical data for GB-401 demonstrates potential advancements in glaucoma treatment.
• Presentation at ARVO Annual Meeting may enhance visibility and credibility in the medical community.

Negative

• None.

BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 2022.

Information is listed below and available on the ARVO website.

In Vitro and In Vivo Characterizations of GB-401, a Sustained-Release Intravitreal Implant Containing a Beta-Adrenergic Antagonist Prodrug for POAG
Presenter: Yun Yu, PhD, Associate Director R&D, Graybug Vision
Poster Session: Drug Delivery
Date and Time: Wednesday May 4, 2022; 12:30 – 2:30 PM MT (2:30 – 4:30 PM ET)
Location: Poster Hall - F0151

A copy of the poster will be made available in the Investors and Media section of the company’s website – in the Medical Events and Publications tab – at the same time.

About Graybug

Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases. The company’s diversified portfolio is designed to treat vision-threatening diseases of the retina, optic nerve, and cornea, by either maintaining effective drug levels in ocular tissues for long periods of time, using innovative technologies, such as injectable sustained-release formulations, or by curing diseases with gene therapies. Graybug’s most advanced drug candidate, GB-102 is a microparticle formulation of a pan-VEGF inhibitor, sunitinib, for the treatment of wet age-related macular degeneration designed for a twice-per-year intravitreal injection. GB-102 has the potential to also benefit patients with diabetic retinopathy. GB-401 is a first-in-class implant formulation containing a novel prodrug of timolol for the treatment of primary open-angle glaucoma (POAG) designed for a twice-per-year intravitreal injection with a proprietary applicator. GB-501 is an adeno-associated virus (AAV) gene therapy with Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to treat corneal clouding caused by mucopolysaccharidosis type 1 (MPS1), a lysosomal storage disorder. GB-601 is being developed as a long-acting formulation of a novel cGMP analog to address hereditary retinal diseases like retinitis pigmentosa, a group of genetic disorders that involve a loss of cells in the retina. GB-701 is being developed as a long-acting formulation of a potent factor B inhibitor targeting the complement cascade which plays a role in AMD. Founded in 2011 based on technology licensed from the Johns Hopkins University School of Medicine, Graybug has offices in Redwood City, California and in Baltimore, Maryland. For more information, please visit www.graybug.vision.

Investor Contact IR@graybug.vision (650) 487-2409

Media Contact media@graybug.vision (404) 384-0067

FAQ

What is the purpose of Graybug Vision's GB-401?

GB-401 is designed as a sustained-release intravitreal implant for the treatment of primary open-angle glaucoma.

When is the ARVO Annual Meeting where Graybug will present data for GB-401?

The ARVO Annual Meeting will take place from May 1-4, 2022.

Where will Graybug Vision present the preclinical data for GB-401?

The data will be presented at the Colorado Convention Center in Denver during the ARVO Annual Meeting.

What type of data will be presented for GB-401?

Graybug will present in vitro and in vivo characterizations of GB-401.

How might GB-401 impact the market for glaucoma treatments?

If successful, GB-401 could represent a significant advancement in the treatment of glaucoma, potentially enhancing market share for Graybug Vision.